Quantcast
Last updated on April 16, 2014 at 1:21 EDT

Latest Pharmaceutical industry in India Stories

2014-03-24 23:24:35

MarketOptimizer.org offers “PharmaPoint: Type 2 Diabetes – Global Drug Forecast and Market Analysis to 2022 – Event-Driven Update” to its store. Dallas, Texas (PRWEB) March 24, 2014 This report focuses on type 2 diabetes pharmaceuticals in seven major markets (US, France, Germany, Italy, Spain, UK, and Japan) and three emerging markets (China, India and Brazil). These 10 markets will be referred to as the global market. The global type 2 diabetes pharmaceutical markets in the 2012...

2014-03-14 12:28:10

GHENT, Belgium, March 14, 2014 /PRNewswire/ -- ActoGeniX NV, creator of ActoBiotics(TM), announced today that Bernard Coulie, Chief Executive Officer, will present a company overview at the 21(st )Annual Future Leaders in the Biotech Industry Conference at 1:30pm ET on Friday, March 28, 2014, at the Millennium Broadway Hotel in New York City. A live webcast of the presentation will be available at the following link: https://www.webcaster4.com/Webcast/Page/392/3742 and on the...

2014-03-13 16:27:50

DUBLIN, Ireland, March 13, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/34kmnx/global_biosimilar) has announced the addition of the "Global Biosimilar Market Outlook 2018" [http://www.researchandmarkets.com/research/34kmnx/global_biosimilar ] report to their offering. <start_newscom> (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The global biosimilars market is at a crucial turning point, as...

2014-03-11 08:28:29

Patented technology could bring up to $167 million in milestone payments plus future long-term residual royalties to Caisson. OKLAHOMA CITY and AUSTIN, Texas, March 11, 2014 /PRNewswire/ -- Caisson Biotech, L.L.C., a biopharmaceutical company with a patented heparosan-based drug delivery technology, HEPtune(TM), announced today that it has expanded the scope of its partnership with global healthcare leader Novo Nordisk A/S (NYSE: NVO). This latest license agreement gives Novo Nordisk...

2014-03-10 08:29:17

INCLINE VILLAGE, Nev., March 10, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced the appointment of David W. Gryska to its board of directors. Mr. Gryska brings more than 30 years of strategic biopharmaceutical and financial leadership experience to PDL and has demonstrated success in implementing successful strategic initiatives, growing companies and executing multi-billion dollar financial transactions....

2014-03-06 23:30:58

Deeper engagement with Association of Strategic Alliance Professionals reflects pharmaceutical leader’s focus on elevating the practice of alliance management within healthcare industry. Canton, Mass. (PRWEB) March 06, 2014 The Association of Strategic Alliance Professionals (ASAP), the world’s leading professional association dedicated to the practice of alliance management, today announced that leading pharmaceutical company Astellas Pharma Inc. has upgraded to Global Member....

2014-03-05 12:27:04

DUBLIN, March 5, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/w2749d/antibody_drug) has announced the addition of the "Antibody Drug Conjugates: Contract Manufacturing Market, 2014 - 2024" [http://www.researchandmarkets.com/research/w2749d/antibody_drug ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The concept of Antibody drug conjugates (ADCs) is simple - a cytotoxic /...

2014-03-05 04:22:29

DUBLIN, March 5, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/ghwrtz/bolus_injectors) has announced the addition of the "Concise Analysis of the International Bolus Injectors Market, 2014 - 2024" [http://www.researchandmarkets.com/research/ghwrtz/bolus_injectors ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The injectable drug delivery market holds significant potential for the...

2014-03-04 16:25:40

CALGARY, March 4, 2014 /PRNewswire/ - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will participate in the 34(th) Annual Cowen and Company Healthcare Conference in a session on Wednesday March 5(th), 2014 at 8:40 a.m. ET. The conference takes place from March 3(rd) to 5(th) at the Boston Marriott Copley Place in Boston, MA. A live audio link to the webcast session will be available at: http://wsw.com/webcast/cowen16/ONCY or on the...

2014-02-25 08:33:10

PHILADELPHIA, Feb. 25, 2014 /PRNewswire/ -- TransCelerate BioPharma Inc. ("TransCelerate") today announced the appointment of Annalisa Jenkins, MBBS, MRCP, Executive Vice President and Head of Global Research and Development at Merck Serono (biopharma division of Merck KGaA, Darmstadt, Germany), as Chair of its Board of Directors, effective immediately. Dr. Jenkins, who previously served as a member of the Board of Directors, will work closely with TransCelerate CEO Dr. Dalvir Gill to...